Biotech stories
Food and agriculture start-ups may see fresh capital as the firm targets software and biology plays after the sector's sharp funding pullback.
Eligible research organisations can now access OpenAI's updated GPT-Rosalind model, as the company widens its life sciences rollout worldwide.
The platform targets manual drug-development bottlenecks, from trial documents to safety case intake, as biopharma seeks faster compliant workflows.
The new specialisation should help healthcare and life sciences firms use governed AI and data tools to speed trials, discovery and patient insights.
AI in life sciences is boosting workflows rather than replacing scientists, as firms navigate regulation, data risks and uneven adoption across markets.
Life sciences firms could avoid costly FDA review delays as the software flags conflicting claims across filings before submissions are sent.
Research teams could see faster target discovery as OpenAI opens GPT-Rosalind to qualified US customers for biology and drug discovery work.
Investor demand for Australian startups is outpacing funding channels, with only 27% willing to commit more than AUD $100,000 to one deal.
The advisory body is meant to steer an expanded Cambridge site aiming to house 9,000 people and about 250 life sciences companies by 2028.
The hub's second year delivered a 21% rise in output, with independent analysis showing it supported 148 jobs across Wellington.
Five days of talks in Cambridge will focus on how deep tech can scale internationally, with energy, AI and investment leaders set to attend.
Artificial intelligence has become the main driver of UK tech value, with venture funding and start-up creation increasingly concentrated in the sector.
Access gaps, not investor appetite, are holding back Australian innovation funding despite 66% already backing startups and new businesses.
The funding will help London-based Apoha commercialise a liquid data layer already used by Boehringer Ingelheim and other pharma groups.
The grants are set to speed the rollout of AI tools across healthcare, manufacturing and finance, helping GTA firms reach market sooner.
Healthtech startups are finding it harder to scale as weaker exits and tighter liquidity help drive Canadian VC investment down to CAD $1 billion in 2025.
The AUD $490 million Waterloo precinct is set to ease Sydney’s lab space shortage as it moves into delivery with major global partners.
The funding could help turn hospital infusions into self-injectable treatments, as the London-founded firm scales microgravity drug crystallisation.
Canada’s health tech sector is struggling to turn strong research into commercial scale, as panellists split over whether policy or private capital should lead.
The move gives UK life sciences firms a new source of scale-up capital as a funding gap has left many promising businesses short of backing.
